Current Foundation Product
Research has reported age-associated declines in NAD⁺ levels in certain tissues and biological contexts. Controlled human studies have examined NMN in relation to circulating NAD⁺ and selected measures of physical function, sleep, muscle metabolism, and exercise physiology.
Ultra Pure™ NMN is the current Foundation Product used during RL100's structured 100-day documentation window.
This page explains the current Foundation Product used within RL100. It does not provide standalone NMN checkout.
What human studies have reported
NMN and the NAD⁺ pathway. NAD⁺ participates in cellular energy transfer, redox reactions, metabolic signaling, DNA-repair activity, and other cellular processes. NMN is a naturally occurring precursor the body can use in NAD⁺ biosynthesis. This defined relationship is one reason NMN has been examined in controlled human research.
The findings below are drawn from the broader human NMN literature. Each finding reflects a defined population, dose, duration, and study material. Full study records are maintained in the HealthspanX Evidence Center.
Six-week, four-arm RCT (placebo / 300 / 600 / 1200 mg/day) in 48 amateur runners on ventilatory-threshold and aerobic-capacity measures.
Analysis in reviewFirst-in-human safety study of single oral NMN doses (100, 250, 500 mg) in ten Japanese men. Well tolerated at all doses; downstream metabolites 2Py and 4Py rose dose-dependently.
Read the full analysis →Two-week RCT in 32 adults aged 55–80 showing pharmaceutical-grade NMN (MIB-626) at 1,000 mg once or twice daily raised blood NAD⁺ substantially versus placebo with a safety profile matching placebo.
Read the full analysis →12-week RCT (n=108) in Japanese adults aged ≥65 comparing morning vs evening 250 mg NMN. Evening dosing improved lower-limb function (5-STS) and reduced drowsiness with the largest effect sizes.
Read the full analysis →12-week randomized trial of 250 mg/day oral NMN in 34 healthy adults aged 40–59, examining arterial stiffness and NAD metabolism markers.
Read the full analysis →These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
Product controls
These are the credentials HealthspanX maintains for Ultra Pure™ NMN as the current Foundation Product.
Purity is verified by HPLC (high-performance liquid chromatography).
A third-party test report is available for each batch.
Manufactured in an NSF-certified cGMP facility.
Review full study analyses, trial populations, doses, endpoints, limitations, and disclosures.
Review Human NMN ResearchReview the available analytical and quality information for the current Foundation Product.
Review Quality InformationThe RL100 documentation window
Human research cannot predict what one person will observe. During RL100, the current Foundation Protocol is kept consistent while the same 12 biological areas are documented at Day 0, Day 30, and Day 100.
Completed before the first dose and then locked for the window.
The same biological areas are recorded again under the ongoing protocol.
The Outcome Report compares Day 100 with the locked Day 0 baseline. Vitality Delta™ is reported here only.
Common questions
Start RL100 directly, review the research, or begin with the optional Radiant Life™ Assessment.
Selected research references
Liao B, et al. Journal of the International Society of Sports Nutrition. 2021. PMID 34238308. (Analysis in review.) · Junichiro Irie, et al. Endocrine Journal. 2020. PMID 31685720. · Karol M. Pencina, et al. The Journals of Gerontology: Series A, Biological Sciences and Medical Sciences. 2023. PMID 35182418. · Mijin Kim, et al. Nutrients. 2022. PMID 35215405. · Katayoshi T, et al. Scientific Reports. 2023. PMID 36797393.
